Showing results (91-100 of 292) with videos related to
Sort By:
Pageof 30
Vaccine|January 11, 2012
The challenge of post-implementation surveillance for novel meningococcal vaccinesMatthew D Snape, Duccio Medini, Scott A Halperin, et al.Plos One|August 6, 2025
Exploring the participant experience in controlled human infection model (CHIM) trials: A modified grounded theory studyAnna G Mack, Donna M Halperin, Bailey M Selig, et al.The Pediatric Infectious Disease Journal|February 12, 2009
The impact of childhood meningococcal serogroup C conjugate vaccine programs in CanadaJulie A Bettinger, David W Scheifele, Nicole Le Saux, et al.The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|March 2, 2012
Heterogeneity of rotavirus testing and admitting practices for gastroenteritis among 12 tertiary care pediatric hospitals: Implications for surveillanceJulie A Bettinger, Kathryn Wills, Nicole Le Saux, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2002
Carotid artery dissection as a possible severe complication of pertussis in an adult: clinical case report and reviewDanuta M Skowronski, Jane A Buxton, Morris Hestrin, et al.The Pediatric Infectious Disease Journal|August 29, 2012
The disease burden of invasive meningococcal serogroup B disease in CanadaJulie A Bettinger, David W Scheifele, Nicole Le Saux, et al.Journal of the Pediatric Infectious Diseases Society|December 12, 2018
Burden of Children Hospitalized With Pertussis in Canada in the Acellular Pertussis Vaccine Era, 1999-2015Bahaa Abu-Raya, Julie A Bettinger, Otto G Vanderkooi, et al.Vaccine|October 21, 2006
Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adultsScott A Halperin, Joanne M Langley, Bruce Smith, et al.The Pediatric Infectious Disease Journal|May 1, 2007
Immunologic considerations for the timing of the booster dose of 7-valent pneumococcal conjugate vaccine in young childrenDavid W Scheifele, Scott A Halperin, Jan J Ochnio, et al.Lancet Regional Health. Americas|November 29, 2023
Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation studyAffan Shoukat, Elaheh Abdollahi, Alison P Galvani, et al.Pageof 30